78912
document
Treatment of adult asthma : controlled double-blind clinical trial of oxitropium bromide . Sixteen young adult sufferers from extrinsic paroxysmal asthma with pollen hypersensitivity took part in a therapeutic trial of the synthetic anticholinergic agent oxitropium bromide administered by a metered dose inhaler . The study comprised three 3-week periods . The first , run-in period was carried out to confirm the ability of the patients to maintain a daily record of symptoms . During the second and third periods , the patient received 3 X 2 inhalations of drug or placebo in a cross-over design . The medical staff was blind to the nature of the aerosol ( drug or placebo ) , which was given in random order . The run-in clinical score was high . Asymptomatic days were relatively infrequent and daily drug consumption was high . Functional studies between the cross-over periods showed flow-rate values close to normal , with an increase in residual volume and functional residual capacity . During treatment either with placebo or oxitropium , there was a statistically significant decrease in clinical scores . Results for oxitropium bromide treatment were significantly better than the run-in values ( p less than 0.005 ) and the placebo period ( p less than 0.02 ) . There was no significant change in non-trial drug consumption . Functional values showed no difference in terms of flow rate , although oxitropium did cause a significant improvement in the RV/TLC ratio ( p less than 0.05 ) . No adverse reactions were reported .
78913
Intervention_Pharmacological
oxitropium bromide
78914
Intervention_Pharmacological
synthetic anticholinergic agent oxitropium bromide
78915
Intervention_Control
placebo
78916
Intervention_Pharmacological
drug
78917
Intervention_Control
placebo )
78918
Intervention_Control
placebo
78919
Intervention_Pharmacological
oxitropium
78920
Intervention_Pharmacological
oxitropium bromide
78921
Intervention_Control
placebo
78922
Outcome_Physical
Asymptomatic days
78923
Outcome_Mental
daily drug consumption
78924
Outcome_Other
flow-rate values
78925
Outcome_Physical
residual volume and functional residual capacity .
78926
Outcome_Physical
clinical scores
78927
Outcome_Physical
significantly better
78928
Outcome_Physical
run-in values
78929
Outcome_Mental
non-trial drug consumption
78930
Outcome_Physical
flow rate
78931
Outcome_Physical
RV/TLC ratio
78932
Outcome_Physical
adverse reactions
78933
Participant_Condition
adult asthma :
78934
Participant_Condition
Sixteen young adult sufferers from extrinsic paroxysmal asthma with pollen hypersensitivity took part in a therapeutic trial of the synthetic anticholinergic agent oxitropium bromide administered by a metered dose inhaler .